A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

NCT07234773 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: KT501

Sponsor

Kali Therapeutics, Inc.